Results 1 to 10 of about 6,155 (167)

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) [PDF]

BMC Cancer
Background Targeting RAS mutant (MT) colorectal cancer (CRC) remains a difficult challenge, mainly due to the pervasiveness of RAS/MEK-mediated feedback loops. Preclinical studies identified MET/STAT3 as an important mediator of resistance to KRAS-MEK1/2
Francesca Aroldi, Elena Elez, Thierry André, Geraldine Perkins, Hans Prenen, Vlad Popovici, Peter Gallagher, Jennifer Houlden, Linda Collins, Corran Roberts, Christian Rolfo, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Karolien Bettens, Jurgen Delfavero, Victoria Coyle, Mark Lawler, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Bryan T. Hennessy, Alberto Bardelli, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium   +31 more
doaj   +4 more sources

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy [PDF]

Case Reports in Gastroenterology, 2022
Encorafenib, a BRAF kinase inhibitor, in combination with binimetinib, a selective MEK inhibitor have known gastrointestinal adverse events; however, adverse colitis events have not been well studied.
Aaron G. Issac, David Szafron, Dongguang Wei, Jennifer L. McQuade, Yinghong Wang   +4 more
doaj   +3 more sources

The safety and efficacy of encorafenib plus binimetinib for brain metastases: a systematic review and meta-analysis [PDF]

Discover Oncology
Purpose Brain metastases (BMs) present a significant therapeutic challenge due to limited blood-brain barrier permeability, which restricts the efficacy of systemic treatments.
Amirmohammad Bahri, Ali Dehghan Banadaki, Mobina Bayani, Ibrahim Mohammadzadeh, Milad Shafizadeh, Mohammad Amin Habibi, Bardia Hajikarimloo   +6 more
doaj   +2 more sources

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study [PDF]

BMC Cancer
Background In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the MEK1/MEK2 inhibitor binimetinib ...
Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang, Eric Van Cutsem   +8 more
doaj   +2 more sources

Ophthalmic Toxicities in BEACON Triplet Therapy for BRAF V600E-Mutant Colorectal Cancer: A Case Series [PDF]

Journal of the Anus, Rectum and Colon
The BEACON regimen, comprising cetuximab, encorafenib, and binimetinib, is a critical treatment for BRAF-mutant metastatic colorectal cancer (mCRC). While effective, this regimen may be associated with a high frequency of serous retinal detachment (SRD ...
Hayato Nakamura, Kiyoshi Suzumura, Kazuhiro Oiwa, Tomonori Tsuchiya, Kazumi Nishimae, Masahiro Tanaka, Masaki Terasaki, Yoshichika Okamoto   +7 more
doaj   +2 more sources

and inhibition as treatment strategies in V600E metastatic colorectal cancer [PDF]

Therapeutic Advances in Medical Oncology, 2021
Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling.
Javier Ros, Iosune Baraibar, Emilia Sardo, Nuria Mulet, Francesc Salvà, Guillem Argilés, Giulia Martini, Davide Ciardiello, José Luis Cuadra, Josep Tabernero, Elena Élez   +10 more
doaj   +2 more sources

Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report [PDF]

Gynecologic Oncology Reports
Background: Treatment of recurrent chemotherapy, aromatase (AI) and MEK Inhibitor (MEKi) resistant low grade serous ovarian cancer (LGSOC) remains a challenge. Novel treatment options for KRAS mutated MEKi resistant LGSOC are warranted.
Victoria M. Ettorre, Luca Palmieri, Sarah Ottum, Michelle Greenman, Alessandro D. Santin   +4 more
doaj   +2 more sources

Severe symptomatic cardiac dysfunction in a patient with BRAF V600E-mutated metastatic colorectal cancer treated with encorafenib, binimetinib, and cetuximab: a case report [PDF]

Journal of Pharmaceutical Health Care and Sciences
Background V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations are present in approximately 5% of Japanese patients with colorectal cancer (CRC) who receive BRAF-targeted triplet therapy, consisting of encorafenib (a BRAF inhibitor ...
Masahiro Kondo, Yukiko Nagao, Shohei Hayashi, Eri Wakita, Masato Noda, Itsuki Okada, Chiharu Wachino, Keiko Yamada-Nishide, Masayuki Hori, Yuji Hotta, Yoichi Matsuo, Yoko Furukawa–Hibi   +11 more
doaj   +2 more sources

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. [PDF]

Clin Cancer Res
Targeted therapy; Metastatic melanoma; BRAFV600-mutantTeràpia dirigida; Melanoma metastàtic; Mutació BRAFV600Terapia dirigida; Melanoma metastásico; Mutación BRAFV600Purpose: LOGIC 2 (NCT02159066), a multicenter, open-label, two-part, phase II study ...
Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, Muñoz-Couselo E, Burris HA, Postow MA, Chmielowski B, Middleton MR, Berking C, Hassel JC, Gesierich AH, Mauch C, Kleha JF, Polli A, Harney AS, di Pietro A, Ascierto PA.   +20 more
europepmc   +3 more sources

A plain language summary of the molecular changes in the tumors of people with BRAF V600E-mutant colorectal cancer in the BEACON study. [PDF]

Future Oncol
Colorectal cancer; MutationCàncer colorectal; MutacióCáncer colorrectal; MutaciónWhat is this summary about? This summary discusses the genetic and molecular changes in tumors of participants with BRAF V600E–mutant metastatic colorectal cancer who were ...
Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J.   +13 more
europepmc   +3 more sources